NCT04873765View on ClinicalTrials.gov

Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 18, 2022

Primary Completion Date

August 18, 2022

Study Completion Date

September 18, 2022

Conditions
Neutropenia
Interventions
BIOLOGICAL

Pegfilgastrim Megalabs

Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose

BIOLOGICAL

Pegfilgastim Amgen

Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose

Trial Locations (1)

11300

Marcos Giusti, Montevideo

All Listed Sponsors
lead

Megalabs

INDUSTRY